Global Antidepressants Drugs Market By Product (Selective Serotonin Reuptake Inhibitors, Serotonin Norepinephrine reuptake inhibitors, Tricyclic antidepressant, Monoamine Oxidase Inhibitor, Others), By Depressive Order (Major Depressive order, Obsessive Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others), By Distribution Channel (Online, Offline), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Antidepressants Drugs Market size is expected to be worth around USD 30.5 Billion by 2033, from USD 13.8 Billion in 2023, growing at a CAGR of 7.5% during the forecast period from 2024 to 2033.

A class of therapeutics that aids to treat depression and other mental illnesses are known as antidepressant drugs. There are diverse antidepressants each having particular working mechanism depending upon the mental condition of patients, such as imipramine exert their action by inhibiting serotonin and norepinephrine uptake. In addition, it also suppresses the detrusor contraction and enhance outlet resistance by urether sphincter contration.

A healthcare provider might recommend antidepressants for chronic pain or insomnia anxiety. Depression symptoms may vary, and one antidepressant might be better at relieving some of them than another. A variation is noticed in the symptoms of antidepressants, starting with one medication, then onto the next and from one individual to another.

Some of the side effects associated with antidepressants encircles weight gain, nausea, sexual side effects or dry mouth, making it a challenge to align with the treatment. Many a times serious side effects are noticed when antidepressants are consumed in combination with other medications.

The demand for antidepressant drugs scaled with escalating number of depression cases, rising recognition regarding depression and arrival of novel biologics, fueling the dimensions of antidepressant drugs market. Common cause of depression include social isolation and stressful work environment, leading to rising incidences of depression across the globe.

Furthermore, in countries such as United States and United Kingdom, the percentage of population affected by depression is high in every age group. However, the market for antidepressant drugs may impede in the near future, by virtue of rising preference for non-pharmacological therapies over pharmacological one coupled with the serious side effects associated with antidepressant drugs.

• According to World Health organization updated in September 2021, depression if a prevalent mental illness and approximately 5% of adults experience depression globally.
• According to Anxiety and Depression Foundation data, in January 2022, generalized anxiety disorder affected 6.8 million adults annually or 3.1% of the US population.

Key Takeaways

• Based on product, Selective Serotonin Reuptake Inhibitor segment showcased its dominance in the global antidepressant drugs market in the year 2023.
• Based on depressive order, a laudable market share of 42.3% is withheld by major depressive disorder segment.
• Based on distribution channel, the need to visit physicians face to face and take over the counter drugs, led offline segment to rule the market.
• North America owing to rising prevalence of mental disorders, dominates the antidepressant drugs market in 2023.
• Severe side effects associated with antidepressant drugs can impede its market in the near future.

Product Analysis

A major market portion is grabbed by selective serotonin reuptake inhibitor segment

Based on product, the global antidepressant drugs market is majorly classified into Selective Serotonin Reuptake Inhibitors, Serotonin Norepinephrine reuptake inhibitors, Tricyclic antidepressant, Monoamine Oxidase Inhibitor and Other segments. Amongst these, a remarkable market revenue share of 39.4% is encircled by Selective Serotonin Reuptake Inhibitor segment, dominating the market in the year 2023.

The segmental dominance owes to the major use of segment to treat mental health diseases, including anxiety disorder, depression and other psychiatric condition. The antidepressants mechanisms by preventing serotonin from being reabsorbed, which raises the serotonin levels, thus now acting as a first line of treatment for depression. The drug in addition associates lower possibility of adverse effects that are common to diverse other antidepressant drugs such as constipation, blurred vision and dry mouth.

• According to a survey conducted in 2023, among 787 medical students in North India, students who are often subjected to intense pressure to perform and compete, usually experience anxiety and depression. A percentage of these students-37.2% had suicidal thoughts, 10.9% had plans to commit suicide and 3.3% had attempted suicide.

The fastest growth is witnessed by Serotonin Norepinephrine reuptake inhibitor segment owing to its wide use in treating wide range of depression symptoms. When compared to certain other antidepressant classes, the combined effect of serotonin and norepinephrine pathways may offer a more all encompassing therapeutic effect.

Depressive Order Analysis

Major Depressive disorder segment marks its dominance

Based on depressive order, the market is classified into Major Depressive disorder, Obsessive Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other segments. Major depressive order segment came up as a frontrunner in the global antidepressant drugs market, capturing a laudable market revenue share of 42.3% in the year 2023. This disorder comprise a combination of biological, psychological and social sources of distress.

Some of the significant risk factors include crucial life changes, chronic health problems, substance abuse, family history and certain medications. For such condition, doctors often prescribe antidepressants such as selective serotonin reuptake inhibitors for treatment purpose. The market experiences a forward push with rising number of major depressive order cases across the globe.

• According to World Health Organization data published in September 2021, 5.7% of adults older than 60 years are dealing with depression and approximately 282.1 million people have depression across the globe.
• According to National Institute of Health, around 21 million adults in the United States suffered from at least one major depressive episode.

Distribution Channel Analysis

Impressive market share of 84.5% is captured by offline segment

Based on distribution channel, the major is subjective to two segments including offline and online segments. Offline segment showcased noticeable growth capturing an impressive market revenue share of 84.5% in the year 2023.

The reason behind such a robust growth is antidepressant drugs frequently need a prescription, and patients usually see doctors in person for diagnosis and prescription. While dealing with mental health conditions, patients and healthcare professionals usually have a close-knit and continuing interaction, thus scaling the offline segment prominence.

Online segment on the flip side showcase fastest growth in recent years. This is because of online sites providing more ease for people to learn about antidepressant medication, allowing them to have a through research and educate themselves about the alternatives without actually having physical visits towards physicians or pharmacies.

Key Market Segments

By Product

• Selective Serotonin Reuptake Inhibitor
• Serotonin Norepinephrine reuptake inhibitors
• Tricyclic antidepressant
• Monoamine Oxidase Inhibitor
• Other

By Depressive Order

• Major Depressive disorder
• Obsessive Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Other

By Distribution Channel

• Offline
• Online

Drivers

Rising pervasiveness of mental disorders

The rising prevalence of mental disorders is the primary factor leading to the robust market drive. More the cases of mental illness, more it necessitates the demand for mental condition treatment, including antidepressant drugs.

• According to Anxiety and Depression Association of America, anxiety disorders are the most common mental disorders in the US, affecting 41 million adults or around 18.1% of the total population each year.
• According to World Health Organization, around 7.5% of people in India suffer from some of mental disorder every year.

Introduction of innovative drug candidates

Major market players have a strong emphasis to introduce new and innovative treatments for disorders related to mental health. Due to this reason, there is growing research and development efforts for novel discoveries evaluating combination treatments with existing and new therapeutic molecules, leading to lucrative potential for the development of innovative drug formulations for treating mental disorders and neurology conditions including depression. In addition to this, funding support from government is boosting the global market growth.

Restraints

Social stigmas restraining the market growth

The fear of being judged and discriminated if seeking therapy is still the biggest social stigma among people dealing with mental disorders, unbaling them to take antidepressants and consult a physician. This occurs due to lack of knowledge and awareness regarding mental health concerns, its medications and efficaciousness. There is a stigma associated with publicly discussing mental health issues in some communities, refraining mentally disturbed people from using antidepressants or resist medical assistance together.

Serious side effects impedes the market expansion

Another significant factor resisting people from opting mental health treatments include the side effects associated with current treatments and marketed drugs for depression and other mental disorder. Studies have been found to have severe side effects on normal cells of the body while taking treatment for neurology conditions.

Some of the common side effects include dizziness, blurred vision, and weight gain in several patients, thus limiting the adoption of these drugs by patients. Furthermore, in emerging countries many people do not opt for such mental issues due to limited awareness, social stigma, and lower per capita healthcare expenditures.

• According to World Health Organization, around 90% patient dealing with neurological disorders are devoid of treatment in developing countries. This gap is comparatively narrower in developed countries, where approximately 45% to 65% of people do not opt for treatment.

Opportunities

Customized Treatment Plans

The market for antidepressant drugs gains popularity due to incorporation of customized treatment plan ideas. Many adults suffering from moderate to severe depression experiences severe side effects, resulting into opting of personalized treatment plans. Treatment plans are being customized depending upon patients’ unique genetic composition, biomarkers, and response patterns. This idea of treatment tailors specific treatment plans, allowing for more efficient and effective treatments. The continuous research and development efforts in neuroscience and pharmacogenomics have led to new discoveries for creative therapeutic methods.

Integration of Artificial intelligence and machine learning

The market is further accelerating with the integration of artificial intelligence and machine learning, enabling physicians to uncover possible medication candidates by analysis of large datasets. This has effectively minimized the duration and expense required to get new antidepressant medications to the market by speeding up the durg discovery process. In addition, such technologies are allowing mental health patients to be remotely monitored by medical professionals and bring out desired outcomes and make necessary drug adjustments.

Latest Trends

Behavioral Activation Therapy

The therapy involved working with a depressed person to increase activities that can reduce their depression. This therapy stems from another type of talk therapy, i.e., cognitive behavioral therapy which is as effective as antidepressant drugs. The approach also benefits people dealing subclinical symptoms of depression or anxiety.

Cranial Electrotherapy Stimulation Devices

It is a form of neurostimulator that aids to deliver a small, pulsed alternating current through electrodes on the head. The technology is employed with the intention to treat a variety of conditions including anxiety, depression and insomnia.

Impact of Macroeconomic factors

With the rising population, there is rise in the number of individuals experiencing mental health issues including depression. This necessitates an ultimatum for advanced medical treatments including antidepressant drugs. Depression is commonly experienced by elderly population, such as late life depression or mood disorders linked with chronic conditions.

This drives up the demand for antidepressant medications developed depending upon the need of older population. Nowadays, there are noticeable number of people dealing with anxiety, stress or depression as there is rising urbanization and sedentary lifestyles associated with modernization, influencing the mental health in a nevative manner. Thus, these factors contributes to rising cases of mental disorders, thus leading to the growth of global antidepressant drugs market.

Regional Analysis

North America Region Accounted for Significant Share of the Global Antidepressants Drugs Market

North America to witness lucrative market growth in the year 2023, capturing a commendable market revenue share of 35.3%. the region dominates the market owing to increasing number of cases of depression particularly in the United States. The region has a scaling geriatric population and product launches, generating numerous market opportunities. In addition, high concentration of market players acquisition and partnerships among major market players are some of the another factors driving the market growth.

• According to Anxiety and Depression Association, 2021, more than 16.1 million American adults suffers from major depressive disorders each year, which is more prevalent in women than men.
• In May 2022, a new generic drug, pms-LURASIDONE was launched by Pharmascience Canada in the Canadian market, which is a monotherapy for management of manifestations of schizophrenia in adults and adolescents (13-17 years of age).

Key Regions and Countries

• North America
  • The US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The market for antidepressant drugs comprises a combination of domestic and multinational players. There are minimal entry barriers and most drugs are available over the counter. Major market players are involved in the global expansion of their product portfolio through mergers, acquisitions and partnerships, thereby expanding their market reach.

Market Key Players

• GlaxoSmithKline Plc.
• AstraZeneca
• Sanofi
• Eli Lilly & Company
• Pfizer Inc.
• Bristol-Meyer Squibb
• Merck & Co Inc.
• Janssen Pharmaceuticals
• Sandoz Inc.
• Opko Health
• Novartis AG
• Sun Pharmaceuticals Pvt Ltd.
• Intra-Cellular Therapies

Recent Development

• In July 2023: ‘Breyna Inhalation Aerosol’, the primary conventional variant of AstraZeneca’s Symbiocort was launched by Viatris Inc. and Kindeva Drug Delivery LP. The drug is approved by the  United States Food and Drug Administration, proving beneficial to treat patient with asthma or chronic obstructive pulmonary disease.
• In August 2023: ‘ZURZUVAE 50 mg’, is approved by US Food & Drug Administration. The drug is for individuals for postpartum depression, according to a statement by Biogen Inc. and Sage Therapeutics.

Report Scope